International Clinical Trial: A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages =65 Years

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (EUCTR2026-000221-16-Outside-EU/EEA) titled 'A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages =65 Years' on Sept. 28.

Study Type: Interventional clinical trial of medicinal product

Study Design: Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 4

Primary Sponsor: BioNTech SE

Condition: COVID...